2022

Duopharma Biotech to Commercialise SCM Lifescience’s Stem Cell Based Hair Care Products in Malaysia and Region Under its Consumer Healthcare Business.

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.

Duopharma Biotech Delivers Better Earnings in 2Q 2022

Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.

Duopharma Biotech And The Live Green Co To Develop Plant-Only Wellness Foods and Plant Based Pharmaceuticals in Malaysia

KUALA LUMPUR, 14 JULY 2022 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) and US-based foodtech company The Live Green Co. signed a Collaboration Agreement today to explore the use of plant ingredients and technology to replace animal, synthetic and ultra-processed ingredients, to meet consumer demand for more sustainable wellness foods and pharmaceuticals.

Duopharma Biotech Maintains High Productivity Amidst Focus on Innovation

● Duopharma Biotech Berhad’s 21st AGM reaffirms the Group’s commitment to maintaining its leading position as an innovative pharmaceutical company in Malaysia and a global leader in the halal sector
● Intensified focus on ESG has made the Group a preferred employer, trusted partner, attractive investment and an increasingly strong brand

Duopharma Biotech Spurs Efforts to Capture Global Halal Pharma Market via Halal Pharmaceuticals Symposium

Kuala Lumpur, June 15, 2022 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company“) hosted the Third (3rd) Halal Pharmaceuticals Symposium 2022 today, as part of The Company’s continuing quest to spearhead efforts to capture the global halal pharmaceuticals market by facilitating the sharing of best practices, achievements and international collaborations to resolve challenges, advance global standards and jointly shape the industry.

Duopharma Biotech Posts Improved 1Q 2022 Performance

● 1Q 2022 PBT increased by 15% to RM26.65 million compared to previous corresponding quarter
● Revenue gained 12% to RM185.94 million year-on-year
● Improving Malaysian economy, recovery in domestic demand bode well for Duopharma Biotech’s prospects

Duopharma Biotech Pledges Carbon Neutrality and Net Zero Goals ESG Roadmap Targets Carbon Neutrality to be Achieved by 2030 and Net Zero by 2050

Kuala Lumpur, 30 March 2022 – The Board of Directors of Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) wishes…

Uphamol Signs on as Official Analgesic Partner For The Malaysian Football League

Kuala Lumpur, February 25 2022 – Uphamol, the leading paracetamol brand from Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) is now the Official Partner for the Malaysian Football League (MFL) in the Analgesic Category for a two-year period from 1 January 2022 to 31 December 2023, as part of a sponsorship agreement with Duopharma Biotech during this period. The sponsorship agreement will cover the Perlawanan Sumbangsih, Liga Super and Piala Malaysia competitions in 2022 and 2023 respectively.

Proviton STR Signs on as Official Isotonic Partner for The Malaysian Football League 

KUALA LUMPUR, 25 FEBRUARY 2022 – Proviton STR, a leading isotonic drink brand from Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) has signed on as the new Official Partner for the Malaysian Football League (MFL) in the Isotonic category, as part of a two-year MFL sponsorship by Duopharma Biotech, from 1 January 2022 to 31 December 2023. The sponsorship will cover the Perlawanan Sumbangsih, Liga Super and Piala Malaysia competitions in 2022 and 2023 respectively. 

Duopharma Biotech Reports Higher 4Q 2021 Revenue Amidst Challenge of Higher Costs

● 4Q revenue grows 8.5% to RM145.44 million compared to previous corresponding quarter
● Second interim dividend of 1.8 sen per share
● New and extended public sector supply contracts, potential tax savings to bolster future earnings